chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
Published 6 years ago • 136 plays • Length 4:07Download video MP4
Download video MP3
Similar videos
-
5:55
surgery options for nsclc & i-o therapy in egfr-mutations
-
7:35
i-o therapy versus surgery or chemotherapy in nsclc
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
2:03
ivy elkins on pembroluzumab in combination with platinum-based chemo in recurrent egfr/alk nsclc
-
7:10
toward a cure: chemotherapy plus tki in egfr-mutant nsclc
-
5:54
frontline alk, egfr inhibition in non-small cell lung cancer
-
3:24
sequencing of therapies in egfr-mutant nsclc
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
0:48
current role of immunotherapy in egfr-mutant lung cancer
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
9:39
emerging therapies in egfr-positive nsclc
-
6:23
frontline chemo and tki combination in egfr nsclc
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
8:25
egfr & alk/ros1 testing in squamous nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
4:38
egfr tkis as adjuvant therapy in nsclc
-
7:31
mutation testing to guide alk tki selection in nsclc